| Literature DB >> 35514418 |
Tarik A Mohamed1, Abdelsamed I Elshamy2, Mahmoud A A Ibrahim3, Ammar Zellagui4, Mahmoud F Moustafa5,6, Alaa H M Abdelrahman3, Shinji Ohta7, Paul W Pare8, Mohamed-Elamir F Hegazy1.
Abstract
Two sesquiterpenes, 8α-anisate-dauc-4-ene-3,9-dione (webiol anisate) (1) and 10α-acetoxy-6α-benzoate-jaeschkeanadiol (2) as well as, ten known analogues (3-10), and two sesquiterpene coumarins (11-12) were isolated from an organic root extract of Ferula vesceritensis (Fam. Apiaceae). Chemical structures were elucidated based on IR, 1D- and 2D-NMR and HRMS, spectroscopic analyses. With molecular overlap observed between two protease inhibitors that are being examined as anti-COVID-19 drugs, and sesquiterpenes isolated here, metabolite molecular docking calculations were made using the main protease (Mpro), which is required for viral multiplication as well as RNA-dependent RNA polymerase (RdRp). In silico binding-inhibition analysis predicted that select F. vesceritensis sesquiterpenes can bind to these enzymes required for viral replication. Structures of the isolated constituents were also consistent with the chemo-systematic grouping of F. vesceritensis secondary metabolites with other Ferula species. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35514418 PMCID: PMC9056801 DOI: 10.1039/d0ra06901a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Isolated compounds from Ferula vesceritensis.
1H (500 MHz) and 13C (125 MHz) NMR chemical shifts for 1 and 2
| 1 | 2 | |||
|---|---|---|---|---|
|
1H NMR (C5D5N, | 13C NMR (C5D5N) |
1H NMR (CDCl3, | 13C NMR (CDCl3) | |
| 1 | — | 41.1 | — | 48.2 |
| 2 | 2.24 br d (17.4), 3.00 br d (17.4) | 48.9 | 1.68 m, 1.24 m | 37.5 |
| 3 | — | 206.4 | 1.57 m, 1.93 m | 31.2 |
| 4 | — | 143.9 | — | 86.5 |
| 5 | — | 175.2 | 2.11 d (10.8) | 57.7 |
| 6 | 2.74 m, 2.83 m | 21.1 | 5.30 td (10.8, 3.0) | 70.4 |
| 7 | 1.53 m, 2.65 m | 40.7 | 2.53 t (12.0), 2.30 dd (14.4, 3.0) | 41.2 |
| 8 | — | 86.0 | — | 130.2 |
| 9 | — | 205.8 | 5.25 br s | 128.8 |
| 10 | 2.44 d (12.4), 3.11 d (12.4) | 43.0 | 5.22 br s | 80.7 |
| 11 | 2.65 m | 25.5 | 1.95 m | 37.3 |
| 12 | 1.20 d (7.0) | 20.2 | 0.83 d (6.6) | 17.4 |
| 13 | 1.22 d (7.0) | 20.3 | 0.96 d (6.6) | 18.5 |
| 14 | 1.69 s | 21.4 | 1.82 s | 26.4 |
| 15 | 1.04 s | 29.3 | 1.18 s | 15.7 |
| 1′ | — | 166.3 | — | 166.4 |
| 2′ | — | 121.9 | — | 131.5 |
| 3′,7′ | 8.24 d (8.9) | 132.2 | 8.00 d (7.2) | 129.6 |
| 4′,6′ | 7.07 d (8.9) | 114.3 | 7.46 t (7.8) | 128.6 |
| 5′ | — | 164.3 | 7.58 t (7.8) | 133.3 |
| OCH3 | 3.72 s | 55.4 | — | — |
| C | — | — | — | 170.8 |
| CH3, OAc | — | — | 2.07 s | 21.2 |
Fig. 2Selected 1H–1H COSY (−) and HMBC () correlations of 1,2.
Calculated docking scores (in kcal mol−1) and binding features for the identified compounds 1–12 with SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp)
| Compound | Main protease (Mpro) | RNA-dependent RNA polymerase (RdRp) | ||
|---|---|---|---|---|
| Docking score (kcal mol−1) | Binding features (hydrogen bond length in Å) | Docking score (kcal mol−1) | Binding features (hydrogen bond length in Å) | |
| 1 | −9.9 | HIS163 (1.81 Å), GLU166 (2.10, 2.08 Å) | −7.7 | TYR619 (1.99 Å), LYS621 (1.84, 2.05, 2.39 Å), CYS622 (1.78 Å), LYS798 (2.21 Å) |
| 2 | −8.8 | GLY143 (1.95 Å), GLU166 (2.06 Å) | −7.5 | LYS621 (1.96, 2.11 Å) |
| 3 | −6.6 | — | −6.9 | ASP618 (2.23 Å), ASP623 (2.86 Å), CYS622 (2.02 Å), TRP800 (1.96 Å) |
| 4 | −7.4 | GLU166 (2.45 Å) | −6.2 | TRP619 (2.21, 2.05 Å), CYS622 (2.10 Å) |
| 5 | −8.8 | GLY143 (2.08 Å), CYS145 (2.67 Å), GLU166 (2.27 Å) | −6.4 | ASP618 (2.19 Å), TRP800 (1.96 Å), LYS621 (2.77 Å) |
| 6 | −8.5 | HIS163 (2.12 Å), GLU166 (2.70 Å), THR190 (2.41 Å), GLN192 (1.79, 2.20 Å) | −6.4 | ASP618 (2.29 Å), LYS621 (2.09 Å), TRP800 (1.96 Å) |
| 7 | −8.0 | GLU166 (2.24 Å), GLN192 (2.00 Å) | −7.1 | ASP618 (2.26 Å), LYS621 (2.25, 2.52 Å), TRP800 (2.14 Å) |
| 8 | −9.0 | GLY143 (2.47 Å), CYS145 (1.87, 2.67 Å), THR190 (2.89 Å) | −6.4 | ASP618 (2.22 Å), LYS621 (2.20 Å), TRP800 (2.07 Å) |
| 9 | −6.4 | — | −6.5 | ASP618 (2.33 Å), ASP623 (2.95 Å), CYS622 (1.90 Å), TRP800 (2.02 Å) |
| 10 | −9.7 | CYS145 (1.86 Å), GLU166 (2.61 Å), GLN189 (2.80 Å), THR190 (2.75 Å) | −6.9 | LYS621 (1.98 Å), ASP760 (1.81 Å), TRP800 (1.81 Å) |
| 11 | −8.0 | GLU166 (2.20 Å) | −6.4 | TYR619 (2.34 Å), LYS621 (2.74 Å), GLU811 (1.88 Å) |
| 12 | −8.1 | MET49 (3.04 Å), SER144 (2.21 Å), GLN189 (2.92 Å) | −6.6 | ASP623 (2.11 Å), GLU811 (1.74 Å) |
| Darunavir | −8.2 | GLU166 (1.94, 2.88 Å), LEU167 (1.96 Å) | −4.4 | TYR619 (2.11 Å), ASP760 (1.83 Å), GLU811 (2.24, 2.26 Å) |
| Lopinavir | −9.8 | LEU141 (1.96 Å), GLY143 (2.01 Å), SER144 (3.09 Å), HIS164 (2.62 Å) | −7.5 | ARG553 (2.65 Å), LYS621 (3.03 Å), CYS622 (2.59 Å), ASP623 (2.40 Å) |
Fig. 32D and 3D representations of interactions of 1, darunavir, and lopinavir with proximal amino acid residues of the SARS-CoV-2 main protease (Mpro).
Fig. 42D and 3D representations of interactions of 1, darunavir, and lopinavir with proximal amino acid residues of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp).
Fig. 5(A) Venn diagram analysis of 1 and SARS disease genes and (B) STRING PPI network for the top 10 targets identified by network analyzer for 1 as potent SARS-CoV-2 inhibitor.